GlassScriptPhysician profile
Gilberto Luis Vigo
NPI 1790760502
$4,567.69
in general payments reported to CMS, 2019-2025
23 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.68 · 2020: $371 · 2021: $888 · 2022: $931 · 2023: $446 · 2024: $1,087 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $737.54 | 2020-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Amgen INC. | $554.18 | 2020-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $456.73 | 2020-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $452.75 | 2021-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $434.20 | 2020-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $394.03 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $381.88 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $361.13 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.12 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $130.09 | 2022-2025 | Veozah |
| Abbott Laboratories | $114.85 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $87.31 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $59.65 | 2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.40 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $52.26 | 2020-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37.22 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.75 | 2025 | Xifaxan |
| Exact Sciences Corporation | $20.63 | 2025 | The Cologuard Plus Collection Kit |
| Avanir Pharmaceuticals, INC. | $17.06 | 2019 | |
| Currax Pharmaceuticals LLC | $16.51 | 2025 | Contrave |
| Shire North American Group INC | $15.11 | 2019 | |
| Merck Sharp & Dohme LLC | $12.29 | 2021 | |
| Phathom Pharmaceuticals, INC. | $10.00 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Vigo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.